What the research found

Researchers pooled data from three randomized trials comparing two maintenance doses of CagriSema (a combination of cagrilintide and semaglutide) in people with type 2 diabetes. The higher dose (2.4/2.4 mg weekly) produced modestly more weight loss than the lower dose (1.0/1.0 mg)—a difference of about 2 percentage points in body weight reduction. More participants on the higher dose achieved clinically meaningful thresholds: roughly 65% lost at least 10% of body weight versus 55% on the lower dose.

However, the two doses performed similarly for blood glucose control, with no meaningful difference in HbA1c lowering. The higher dose triggered more gastrointestinal side effects (nausea, vomiting, constipation, diarrhea), occurring in about 65% of users compared to 53% on the lower dose. Neither dose showed concerning rates of serious adverse events or dropout due to safety issues.

Why it matters for you

If you're using GLP-1 or dual-agonist therapies to manage metabolic health or body composition, this suggests dose escalation chases weight loss primarily, not blood glucose benefit. The incremental weight advantage of the higher dose fell below what researchers considered clinically meaningful—roughly 2 percentage points less impressive than the 3-point threshold they prespecified.

The GI side-effect trade-off is real and dose-dependent. Roughly one in four additional users experience GI distress moving from 1.0 to 2.4 mg. If you're tracking tolerability or adjusting your protocol based on adherence, this data supports starting conservatively and only escalating if you're chasing maximal weight loss and tolerate GI effects well. For users primarily focused on glucose stability (tracked via CGM or HbA1c), the lower dose appears sufficient.

This also hints at why individualized dosing matters: metabolic goals vary, and so does the cost–benefit calculation of side effects.

Caveats

  • Only three trials included; generalisability depends on their populations and design quality
  • The difference in weight loss, while statistically significant, was small in absolute terms
  • No long-term follow-up data presented; durability of either dose is unclear
  • GI tolerability can improve over time, so the early safety snapshot may not reflect long-term experience
  • This compares only two fixed doses; true dose titration or individualised escalation protocols weren't evaluated